Brief: Paradigm Biopharmaceuticals Says FDA Grants Paradigm Fast Track Designation For OA
12/04/2022 08:52
April 12 (Reuters) - Paradigm Biopharmaceuticals Ltd
PAR.AX :
* FDA GRANTS PARADIGM FAST TRACK DESIGNATION FOR OA-PAR.AX
* U.S. FDA GRANTED FAST TRACK DESIGNATION FOR PHASE 3
PROGRAM
INVESTIGATING PENTOSAN POLYSULFATE SODIUM
Source text for Eikon: ID:nASXSHyGW
Further company coverage: PAR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt